Tenderwize
Wróć do wyszukiwania

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Mar 27, 2027 · 216 days left·Open·Supplies·Framework
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Zolmitriptan (ATC N02CC03).

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active substance Zolmitriptan (ATC N02CC03)
  • Open-house model: all interested and eligible pharmaceutical companies may participate without selection
Pokaż pełne podsumowanie

This is a non-exclusive discount agreement ('open-house model') under § 130a Abs. 8 SGB V for pharmaceuticals containing Zolmitriptan (ATC N02CC03). The AOK Niedersachsen invites all interested pharmaceutical companies to conclude discount agreements without a competitive selection. The agreement period runs from 01 June 2025 to 31 May 2027, with contracts possible at any time during this period. The open-house agreements will be replaced automatically when exclusive discount contracts are awarded (expected 6-8 months after publication of a call for competition). The procedure is not a public contract under EU procurement law; the publication is for transparency purposes. Submission deadlines apply for initial contracts (24 April 2025) and later for monthly join dates. Electronic submission is not allowed; paper submission is required.

Ryzyka

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG or a consortium of such
  • Pharmaceutical products must be authorised for market in Germany under AMG
  • The pharmaceutical entrepreneur must have its registered office within Germany, EU, or EEA (§ 9 Abs. 2 Satz 1 AMG)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

Price (discount) criterion; uniform conditions apply to all participants.

Zamawiający

Lokalizacja

Hannover, DEU

Identyfikator

AOK- Niedersachsen. Die Gesundheitskasse

Działalność

Health

Części (1)

LOT-0000

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

Open-house model for Zolmitriptan (ATC N02CC03) discount agreements. All eligible pharmaceutical companies may join under uniform conditions. Contracts are non-exclusive and will be replaced by exclusive agreements once awarded.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE929, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

Price

Termin

Deadline Mar 27, 2027

Szczegóły zamówienia

Data publikacji
31 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
207292-2025

Podobne przetargi